Attitudes and Difficulties Associated with Benzodiazepine Discontinuation

Long-term use of benzodiazepine receptor agonists (BZDs) may depend on clinicians’ BZD discontinuation strategies. We aimed to explore differences in strategies and difficulties with BZD discontinuation between psychiatrists and non-psychiatrists and to identify factors related to difficulties with BZD discontinuation. Japanese physicians affiliated with the Japan Primary Care Association, All Japan Hospital Association, and Japanese Association of Neuro-Psychiatric Clinics were surveyed on the following items: age group, specialty (psychiatric or otherwise), preferred time to start BZD reduction after improvement in symptoms, methods used to discontinue, difficulties regarding BZD discontinuation, and reasons for the difficulties. We obtained 962 responses from physicians (390 from non-psychiatrists and 572 from psychiatrists), of which 94.0% reported difficulty discontinuing BZDs. Non-psychiatrists had more difficulty with BZD discontinuation strategies, while psychiatrists had more difficulty with symptom recurrence/relapse and withdrawal symptoms. Psychiatrists used more candidate strategies in BZD reduction than non-psychiatrists but initiated BZD discontinuation after symptom improvement. Logistic regression analysis showed that psychosocial therapy was associated with less difficulty in BZD discontinuation (odds ratio, 0.438; 95% confidence interval, 0.204–0.942; p = 0.035). Educating physicians about psychosocial therapy may alleviate physicians’ difficulty in discontinuing BZDs and reduce long-term BZD prescriptions.

[1]  H. Yamashita,et al.  Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics , 2021, Neuropsychopharmacology reports.

[2]  K. Mishima,et al.  Prescribing Pattern of Hypnotic Medications in Patients Initiating Treatment at Japanese Hospitals: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Claims Database , 2021, Drugs - Real World Outcomes.

[3]  N. Watanabe,et al.  Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and meta‐analysis , 2021, Psychiatry and clinical neurosciences.

[4]  N. Stocks,et al.  Primary care management of chronic insomnia: a qualitative analysis of the attitudes and experiences of Australian general practitioners , 2020, BMC Family Practice.

[5]  C. Hughes,et al.  Brief interventions targeting long‐term benzodiazepine and Z‐drug use in primary care: a systematic review and meta‐analysis , 2020, Addiction.

[6]  H. Yamashita,et al.  Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: A systematic review and meta-analysis. , 2019, Sleep medicine reviews.

[7]  K. Mishima,et al.  Long-term use of hypnotics: Analysis of trends and risk factors. , 2019, General hospital psychiatry.

[8]  H. Yasunaga,et al.  Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan , 2019, BMJ Open.

[9]  M. Yosef,et al.  Predictors of Long-Term and High-Dose Use of Zolpidem in Veterans. , 2019, The Journal of clinical psychiatry.

[10]  D. Nutt,et al.  British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update , 2019, Journal of psychopharmacology.

[11]  S. Vinker,et al.  Chronic hypnotic use at 10 years—does the brand matter? , 2018, European Journal of Clinical Pharmacology.

[12]  R. McHugh,et al.  Review: Adjunctive pharmacologic approaches for benzodiazepine tapers. , 2018, Drug and alcohol dependence.

[13]  Ilan Matok,et al.  Z-drugs and risk for falls and fractures in older adults—a systematic review and meta-analysis , 2018, Age and ageing.

[14]  Brian M. Merrill,et al.  Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives , 2018, Journal of clinical medicine.

[15]  B. Glenthøj,et al.  Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. , 2015, The Cochrane database of systematic reviews.

[16]  M. Soyka Treatment of Benzodiazepine Dependence , 2017, The New England journal of medicine.

[17]  Daniel J Buysse,et al.  Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. , 2017, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[18]  T. Wilt,et al.  Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians , 2016, Annals of Internal Medicine.

[19]  D. Greenblatt,et al.  Long-term Therapeutic Use of Benzodiazepines , 2016 .

[20]  M. Farrell,et al.  Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. , 2015, The Cochrane database of systematic reviews.

[21]  J. Pivette,et al.  Did the new French pay-for-performance system modify benzodiazepine prescribing practices? , 2014, BMC Health Services Research.

[22]  P. Blier,et al.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders , 2014, BMC Psychiatry.

[23]  Paul McCrone,et al.  Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology , 2014, Journal of psychopharmacology.

[24]  P. Little,et al.  GPs' management strategies for patients with insomnia: a survey and qualitative interview study. , 2014, The British journal of general practice : the journal of the Royal College of General Practitioners.

[25]  H. Möller,et al.  Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care , 2012, International journal of psychiatry in clinical practice.

[26]  J. Dyas,et al.  General practitioners' preferences for managing insomnia and opportunities for reducing hypnotic prescribing. , 2010, Journal of evaluation in clinical practice.

[27]  Karim M Khan,et al.  Meta-analysis of the impact of 9 medication classes on falls in elderly persons. , 2009, Archives of internal medicine.

[28]  C. O'brien Benzodiazepine use, abuse, and dependence. , 2005, The Journal of clinical psychiatry.

[29]  C. Protopopescu,et al.  Hypnotic and tranquillizer use among general practitioners in south‐eastern France and its relation to occupational characteristics and prescribing habits , 2004, Fundamental & clinical pharmacology.

[30]  D. Greenblatt,et al.  Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. , 1990, Archives of general psychiatry.

[31]  D. Greenblatt,et al.  Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. , 1990, Archives of general psychiatry.

[32]  P. Seeburg,et al.  Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family , 1987, Nature.

[33]  K. Rickels,et al.  Long-term diazepam therapy and clinical outcome. , 1983, JAMA.